207_Combined course Presentations

Future Perspectives…

PACIFIC PD-L1 Phase III Trial Consolidative therapy with Durvalumab vs Placebo

Placebo

Chemoradiotherapy

MEDI 4736 – Durvalumab (PD-L1 inhibitor)

Planned accrual: 702 pts, >100 sites Endpoints: PFS, OS